Rigel Pharmaceuticals (RIGL) announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. Prior to joining Rigel, Dr. Rojkjaer held several leadership positions in clinical development and medical affairs at biotechnology and global pharmaceutical companies, having most recently served as Chief Medical Officer of Sangamo Therapeutics (SGMO).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RIGL:
- Rigel Pharmaceuticals price target raised to $4 from $3 at Citi
- New Corporate Activity and Growth Risk for Rigel Pharmaceuticals – What’s the Latest?
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Rigel Pharmaceuticals reports Q4 EPS 0c, consensus (3c)
- Options Volatility and Implied Earnings Moves Today, March 05, 2024
